Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
November 6, 2025 / Obesity treatment / GLP-1 GIP dual agonist / VK2735 trial Prediabetes reversal / Metabolic syndrome therapy
Viking’s VK2735, a GLP-1/GIP dual agonist, significantly improved cardiometabolic outcomes in a Phase 2 trial, with 78% of prediabetic patients achieving normal glycemic levels after 13 weeks, compared to 29% with placebo.
Impact of preconceptional vertical sleeve gastrectomy on metabolic, cardiovascular and hepatic functions of Sprague Dawley female rats and perinatal consequences
November 7, 2025 / Vertical sleeve gastrectomy / Maternal health risks / Bariatric surgery pregnancy Hepatic fibrosis / Cardiovascular dysfunction
Pre-conception vertical sleeve gastrectomy in rats improved metabolic profiles and fertility but led to hepatic fibrosis and vascular dysfunction, indicating potential long-term cardiovascular risks despite short-term metabolic benefits.
Using CRISPR-Cas9 to uncover and target the genetic basis of obesity
October 10, 2025 / CRISPR obesity treatment / Gene editing therapy / MC4R FTO mutations Precision medicine obesity / Metabolic disease genetics
CRISPR-Cas9 offers a promising gene-editing approach for treating obesity by targeting key genes regulating appetite, metabolism, and thermogenesis—potentially enabling precise, long-term interventions beyond conventional therapies.
Weightlifting beats running for blood sugar control, researchers find
November 5, 2025 / Weightlifting diabetes prevention / Resistance training obesity / Insulin sensitivity exercise / Blood sugar control / Metabolic health benefits
Virginia Tech researchers found resistance training more effective than running in improving insulin sensitivity, reducing visceral fat, and controlling blood glucose in obese mice—highlighting its potential as a powerful intervention for Type 2 diabetes and metabolic health.
Oral GLP-1 reduces body weight, HbA1c for adults with obesity plus type 2 diabetes
November 5, 2025 / Oral GLP-1 therapy / Orforglipron weight loss / Type 2 diabetes treatment / HbA1c reduction / Cardiometabolic health
The ATTAIN-2 trial shows that once-daily oral GLP-1 orforglipron significantly reduces body weight, HbA1c, and improves cardiometabolic markers in adults with obesity and type 2 diabetes, with a safety profile consistent with other incretin therapies.
Lilly moves deeper into RNAi with $1.2B Sanegene obesity deal
November 10, 2025 / RNAi obesity therapy / Lilly Sanegene partnership / Metabolic disease pipeline / Precision medicine obesity / RNA interference drugs
Eli Lilly and Sanegene Bio have entered a $1.2B partnership to develop RNAi-based therapies targeting metabolic diseases, leveraging Sanegene’s tissue-selective delivery platform to potentially address obesity and related conditions with next-generation precision medicines.
Time-restricted eating without calorie cuts doesn’t improve metabolic health, study finds
November 4, 2025 / Time-restricted eating / Intermittent fasting study / Metabolic health outcomes / Circadian rhythm shift / Calorie control fasting
The ChronoFast trial found that time-restricted eating without calorie reduction did not improve metabolic or cardiovascular health in women with overweight or obesity, though it did shift circadian rhythms, challenging assumptions about TRE’s standalone metabolic benefits.
Study provides insights into the obesity–breast cancer link
November 10, 2025 / Obesity breast cancer / Leptin SCD pathway / Estrogen receptor-positive tumors / Metabolic cancer link / Breast cancer treatment targets
New research reveals that leptin-driven activation of stearoyl-CoA desaturase (SCD) promotes growth and spread of estrogen receptor-positive breast cancer, offering a mechanistic link between obesity and cancer—and identifying SCD as a promising therapeutic target.
Prenatal and Early Childhood Exposure to Pesticides Linked to Metabolic Disorders in Males
November 7, 2025 / Pesticide exposure metabolism / Prenatal endocrine disruption / Glyphosate metabolic risk / Sex-specific health effects / Cardiometabolic syndrome
A UC Berkeley CHAMACOS study links prenatal and early-life pesticide exposure—especially to glyphosate, malathion, and permethrin—to higher metabolic disorder risk in young men, revealing sex-specific vulnerabilities in endocrine and cardiometabolic development tied to environmental toxicants.
New drug HU6 cuts liver fat but preserves muscle mass
November 10, 2024 / MASH liver treatment / HU6 fat reduction / Muscle-sparing therapy / Metabolic liver disease / Rivus Pharmaceuticals trial
HU6, an oral therapy from Rivus Pharmaceuticals, significantly reduced liver fat while preserving muscle mass in MASH patients during a Phase 2 trial, showing strong potential as a safe, fat-selective treatment for metabolic liver disease.
Therapies against cellular aging may help treat metabolic diseases
November 5, 2025 / Cellular senescence metabolism / Senotherapeutics obesity treatment / Type 2 diabetes aging / Inflammation metabolic disease / Senolytics metabolic therapy
Senescent cells contribute to metabolic dysfunction by promoting inflammation and fibrosis; emerging senotherapeutics—including senolytics, senomorphics, and senosensitizers—offer promising strategies to treat and potentially prevent obesity-related metabolic diseases like type 2 diabetes and metabolic syndrome.
Aardvark Therapeutics presents data on metabolic obesity pipeline programs
November 4, 2025 / ARD-201 obesity therapy / WE-868 weight loss / Metabolic disease treatment / Lean mass preservation / Glucose control innovation
Aardvark Therapeutics presented promising data on ARD-201 and WE-868 for metabolic obesity, showing weight loss, preserved lean mass, improved glucose control, and novel mechanisms of action, supporting their continued development as next-generation obesity and metabolic disease treatments.
Rivus Pharmaceuticals Announces New Data from Phase 2 M-ACCEL Trial of HU6 in MASH in Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025
November 7, 2025 / HU6 MASH therapy / Liver fat reduction / Muscle-sparing weight loss / Metabolic dysfunction treatment / Rivus Pharmaceuticals trial
Rivus Pharmaceuticals’ HU6 significantly reduced liver fat and abdominal visceral fat while preserving muscle mass in MASH patients, meeting primary and secondary endpoints in the Phase 2 M-ACCEL trial—supporting its promise as a safe, fat-selective metabolic therapy.
Steatotic liver disease and cancer: From pathogenesis to therapeutic frontiers
November 8, 2025 / Steatotic liver disease / MASH HCC progression / Genetic liver cancer risk / MASLD treatment options / GLP-1 liver therapy
This comprehensive review links steatotic liver disease (MASLD, ALD, MetALD) to hepatocellular carcinoma through genetic, metabolic, and immune mechanisms, and outlines emerging therapies—like GLP-1 polyagonists and THR-β agonists—poised to reshape treatment and prevention of liver-related metabolic cancers.
Rare desert berry could transform diabetes treatment
November 7, 2025 / Nitraria roborowskii diabetes / Natural insulin resistance treatment / PI3K AKT pathway / Desert berry metabolism / Botanical diabetes therapy
Extracts from Nitraria roborowskii (“desert berry”) significantly improved insulin sensitivity, glucose control, and lipid metabolism in diabetic mice by reactivating the PI3K/AKT pathway—offering a potential natural, multi-targeted approach for treating metabolic dysfunction in diabetes.
Wegovy Demonstrates Reduction in Liver Injury in MASH Patients
November 10, 2025 / Wegovy MASH treatment / Semaglutide liver health / GLP-1 liver therapy / ESSENCE trial results / Metabolic liver disease
Wegovy (semaglutide 2.4 mg) significantly reduced liver injury in MASH patients in the Phase 3 ESSENCE trial, showing liver health benefits independent of weight loss—suggesting a broader therapeutic role for GLP-1 agonists in metabolic liver disease.
Illumina and Grail Veterans Launch Hepta With First Liquid Biopsy-Native AI That Detects Liver Disease With Tissue-Level Biological Insights
November 5, 2025 / MASH liquid biopsy / cfDNA liver diagnostics / AI chronic disease detection / Non-invasive liver test / Epigenetic biomarker platform
Hepta’s AI-driven liquid biopsy platform accurately detects MASH with tissue-level precision using cfDNA epigenetic signals, achieving a diagnostic AUC of 0.86 and dramatically reducing false positives—offering a scalable, non-invasive diagnostic alternative to liver biopsy and specialized imaging.
New Insights on Fibrotic Immune Profile Driven Cancer Behavior in MASH, With Bruno Cogliati, PhD, DVM
November 10, 2025 / MASH liver cancer / Fibrotic immune phenotype / HCC recurrence risk / Hot cold fibrosis / Immunotherapy liver fibrosis
New research reveals that fibrotic immune phenotypes (“hot” vs. “cold”) in MASH persist post-injury and drive hepatocellular carcinoma (HCC) behavior, suggesting fibrosis-targeted immunomodulation—not just metabolic control—is essential to prevent cancer recurrence and progression in MASH patients.
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025
November 7, 2025 / Pemvidutide liver fibrosis / MASH AI analysis / GLP-1 glucagon therapy / IMPACT trial results / Non-invasive fibrosis markers
Altimmune’s AI-based analysis from the IMPACT Phase 2b trial showed pemvidutide significantly reduced early, advanced, and total liver fibrosis in MASH patients at 24 weeks, supporting its potential as a dual-action GLP-1/glucagon therapy for fibrosis regression.
Metabolic syndrome-related gene signature for prognosis and immune microenvironment prediction in hepatocellular carcinoma
November 7, 2025 / Metabolic gene HCC / Hepatocellular carcinoma prognosis / Tumor immune / microenvironment
KIAA1841 biomarker cancer / HCC stemness prediction
Researchers identified a metabolic syndrome-related gene signature that predicts poor prognosis, stemness, and immunosuppressive microenvironment in hepatocellular carcinoma. Genes like KIAA1841 and TUBA1B emerged as potential biomarkers for monitoring disease progression and guiding immunotherapy strategies.